Coherus BioSciences, Inc.

Coherus BioSciences, Inc. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. The momentum for this stock is not very good. Coherus BioSciences, Inc. is not very popular among insiders. Coherus BioSciences, Inc. is a mediocre stock to choose.

Coherus BioSciences, Inc. is a commercial-stage clinical biologics platform company, which engages i...

News

Coherus Biosciences just downgraded at UBS, here's why

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Evaluating Coherus BioSciences: Udenyca's Success And Loqtorzi's Prospects

SeekingAlpha Evaluating Coherus BioSciences: Udenyca's Success And Loqtorzi's Prospects...\n more…

Strong Performance and Promising Outlook Justify Outperform Rating for Coherus Biosciences

TipRanks Financial Blog In a report released on August 9, Colleen M. Kusy from Robert W. Baird maintained a Buy rating on Coherus Biosciences (CHRS - Research Report), wit...\n more…

CHRS Stock Earnings: Coherus BioSciences Beats EPS, Beats Revenue for Q2 2024

InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nCHRS stock results show that Coherus BioSciences beat analyst estimates for earnings per share and beat on revenue for the second...\n more…

Coherus BioSciences (CHRS) Reports Q2 Loss, Tops Revenue Estimates

Zacks Investment Research Coherus BioSciences (CHRS) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.38 per share a year ago. These figures...\n more…